MCD Clinical Trials

4 recruiting

Frequently Asked Questions

Common questions about MCD clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 2Phase 3

A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis

Minimal Change Disease (MCD)
Bio-Thera Solutions192 enrolled1 locationNCT07499700
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability and PK of SK-09

FSGSMCD
Consun Pharmaceutical Group72 enrolled1 locationNCT07267026
Recruiting
Not Applicable

NEPTUNE Match Study

Nephrotic Syndrome in ChildrenAlport SyndromeFocal Segmental Glomerulosclerosis+6 more
University of Michigan375 enrolled16 locationsNCT04571658
Recruiting
Phase 1Phase 2

JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency

Phelan-McDermid SyndromeSHANK3 Haploinsufficiency
Jaguar Gene Therapy, LLC6 enrolled3 locationsNCT06662188
Recruiting
Phase 2

Atacicept in Multiple Glomerular Diseases

IgANNephrotic SyndromeFSGS+2 more
Vera Therapeutics, Inc.200 enrolled1 locationNCT06983028
Recruiting
Phase 3

A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

Phelan-McDermid Syndrome
Neuren Pharmaceuticals Limited160 enrolled2 locationsNCT07281079
Recruiting
Not Applicable

RB001 Gene Therapy Study in Children With SHANK3-related Phelan McDermid Syndrome (PMS)

Phelan-McDermid SyndromeSHANK3 Haploinsufficiency
Peking University First Hospital8 enrolled1 locationNCT07014020
Recruiting

Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease

Focal Segmental GlomerulosclerosisMinimal Change DiseaseFSGS+1 more
University of Michigan300 enrolled1 locationNCT05650619
Recruiting

Nephrotic Syndrome Study Network

Membranous NephropathyGlomerulosclerosis, Focal SegmentalMinimal Change Disease (MCD)
University of Michigan1,200 enrolled44 locationsNCT01209000